Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson’s disease
Authors:
- Makoto NaoiMNMakoto Naoi
- Wakako MaruyamaWMWakako Maruyama
- 1 August 2009
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 9 (8) , 1233-1250
Abstract
Neuroprotective therapy has been proposed for age-related neurodegenerative disorders, including Parkinson's disease. Inhibitors of type B monoamine oxidase (MAOB-Is), rasagiline and (-)deprenyl, are the most promising candidate neuroprotective drugs. Clinical trials of rasagiline in patients with Parkinson's disease suggest that rasagiline may have some disease-modifying effects. Results using animal and cellular models have proved that the MAOB-Is protect neurons by the intervention of 'intrinsic' mitochondrial apoptotic cascade and the induction of prosurvival antiapoptotic Bcl-2 and neurotrophic factors. Rasagiline-related MAOB-Is prevent mitochondrial permeability transition induced by various insults and activation of subsequent apoptotic cascades: cytochrome c release, casapase activation, and condensation and fragmentation of nuclear DNA. MAOB-Is increase transcription of prosurvival genes through activating the nuclear transcription factor-(NF) system. Rasagiline increases the protein and mRNA levels of GDNF in dopaminergic SH-SY5Y cells, whereas (-)deprenyl increases those of BDNF. Systemic administration of (-)deprenyl and rasagiline increases these neurotrophic factors in the cerebrospinal fluid from patients with Parkinson's disease and nonhuman primates. This review presents recent advances in our understanding of the neuroprotection offered by MAOB-Is and possible evaluation of neuroprotective efficacy in clinical samples is discussed.Keywords
This publication has 197 references indexed in Scilit:
- 1-Methyl-4-phenyl-pyridinium ion-induced oxidative stress, c-Jun phosphorylation and DNA fragmentation factor-45 cleavage in SK-N-SH cells are averted by selegilineNeurochemistry International, 2008
- Fas-associated factor 1 and Parkinson's diseaseNeurobiology of Disease, 2008
- Structural insights into the mechanism of amine oxidation by monoamine oxidases A and BArchives of Biochemistry and Biophysics, 2007
- A tale of two mitochondrial channels, MAC and PTP, in apoptosisApoptosis, 2007
- Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s diseaseBiochemical and Biophysical Research Communications, 2006
- Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson’s diseaseBiochemical and Biophysical Research Communications, 2006
- Novel cytoprotective mechanism of anti-parkinsonian drug deprenyl: PI3K and Nrf2-derived induction of antioxidative proteinsBiochemical and Biophysical Research Communications, 2006
- NF-κB at the crossroads of life and deathNature Immunology, 2002
- Modulation of [3H]quinpirole binding at striatal D2 dopamine receptors by a monoamine oxidaseA-like site: Evidence from radioligand binding studies and D2 receptor- and MAOA-deficient miceLife Sciences, 2001
- (−) deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male ratsLife Sciences, 1991